Transgene SA

As of December 31, 2024, Transgene SA carries a market capitalization of 90.36M, placing it among publicly traded companies globally. Its enterprise value stands at 73.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Transgene SA's next confirmed earnings release is scheduled for March 31, 2027.

As of December 31, 2024, Transgene SA has 132.29M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Transgene SA maintains a current ratio of 1.48, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, Transgene SA's stock has declined approximately 49.59% over the past 52 weeks. The 50-day moving average sits at 0.79, while the 200-day moving average is 0.79.

As of December 31, 2024, Transgene SA holds 16.67M in cash and equivalents against 17,000.00 in total debt, resulting in a net debt position of -16.67M. Total book value stands at 15.20M, with working capital of 6.68M providing operational flexibility.

Transgene SA's most recent stock split took place on June 18, 2019 with a 39:40 split ratio.